Bryan, Garnier & Co acts as Sole Bookrunner on Oncodesign Precision Medicine’s EUR 8 million Follow-on Offering & IPO on Euronext Growth Paris

Oncodesign Precision Medicine (OPM) is a French listed biopharmaceutical company specialised in cancer.

OPM, previously listed on Euronext Access + in October 2022 through direct listing, is the result of Oncodesign’s split in two different entities: Oncodesign Services, focused on CRO services for pharmaceutical companies, and Oncodesign Precision Medicine developping a pipeline of drug supported by AI.

Oncodesign Precision Medicine’s mission is the discovery of effective treatments for resistant and advanced cancers. It is an innovative biopharmaceutical company specialising in precision medicine, capable of discovering new therapeutic and diagnostic molecules, developing new technologies and supporting the clinical development of its compounds.

The main projects are:
– Develop two Nanocyclix® drug candidates for immuno-inflammatory and Parkinson’s diseases;
– Demonstrate efficacy of ODS-101 (RIPK2 inhibitor) in Phase II and sign a pharmaceutical partnership for the immuno-inflammatory disease market;
– Contribute to the development of LRRK2 inhibitor in partnership with Servier Laboratories.
Follow-on Offering proceeds will be mainly used to pursue the clinical development of RIPK2 and to fund liquidity needs over the next twelve months

Acting as Sole Bookrunner, Bryan, Garnier & Co helped to deliver a EUR 8m follow-on Offering and IPO on Euronext Growth for Oncodesign Precision Medicine.

This is the 2nd time in 2022 that Oncodesign relies on Bryan, Garnier & Co’s services, after the sale of its CRO activities to Elyan Partners for EUR 100m and the concomitant spin-off of its Biotech/AI activities and Listing on Euronext Access +.

OPM raised EUR 8m through an oversubscribed transaction with a priority period for shareholders.

This is Bryan, Garnier & Co’s 6th European healthcare capital increase on Euronext Paris in 2022, demonstrating our continued support to European healthcare companies.

Oncodesign Precision Medicine (OPM), the result of the transfer of Oncodesign’s Biotech and AI activities, is a biopharmaceutical company specialising in precision medicine to treat resistant and metastatic cancers.

OPM’s innovative technologies are: (i) OncoSNIPER for the selection of therapeutic targets using artificial intelligence; (ii) Nanocyclix® for the design and selection of macrocyclic small molecule kinase inhibitors and (iii) Theranostics for the design and selection of radiolabelled biological molecules for systemic radiotherapy.

From these technologies, OPM has built a portfolio of therapeutics. Two drug candidates based on the Nanocyclix technology are expected to enter clinical trials in 2022, one in partnership with SERVIER (which has exercised its option for an exclusive worldwide licence on the programme) to treat Parkinson’s disease and ODS 101 with OPM for the treatment of chronic immuno-inflammatory diseases. Finally, OPM is also collaborating with Servier to discover new therapeutic targets for the treatment of pancreatic adenocarcinoma based on its OncoSNIPER technology. In addition, OPM is seeking a partner for Florepizol, a radiotracer specific for the mutated EGFR target, which has successfully completed Phase 1. Two projects are in early partnership with TIUM BIO (pulmonary fibrosis) and SEngine in oncology. Finally, OPM has a significant portfolio of early stage projects with Nanocyclix® and Theranostics in oncology. With this portfolio of molecules and diversified therapeutic targets.

OPM is headquartered in Dijon, France, and listed on Euronext Growth Paris (Ticker symbol: ALOPM).